全膝关节置换术前后一年的费用分析
该研究回顾了2020至2022年单中心连续13,117例初次全膝关节置换术患者,采用Medicare和单一商业保险索赔数据分析术前12个月和术后12个月的非手术治疗费用。结果显示术后一年总费用较术前下降,且三组患者达到KOOS-JR最小临床重要差异的比例相似。结论认为初次全膝关节置换术患者术后一年费用低于术前非手术治疗年费用,需进一步研究评估非手术治疗模式的成本效益。
要点
- 初次全膝关节置换术患者术后一年总费用较术前一年下降。
- Medicare患者在术前一年接受非手术治疗次数最多(6.5次 vs 5.3次 vs 5.1次,P < 0.001)。
- 三组患者达到KOOS-JR最小临床重要差异的比例相似(74.8% vs 75.6% vs 72.7%,P = 0.35)。
核心结论
- 初次全膝关节置换术患者术后一年费用低于术前一年尝试非手术治疗的费用。
- 需进一步研究评估非手术治疗模式的成本效益。
研究设计与样本
- 回顾性分析2020至2022年单中心连续13,117例初次全膝关节置换术患者,使用Medicare和单一商业保险索赔数据。
主要发现
- 术前一年至术后一年平均总费用:商业保险从760美元降至598美元,Medicare Advantage从583美元降至351美元,Medicare从580美元降至370美元。
- 术前一年非手术治疗次数:Medicare患者6.5次,商业保险患者5.3次,Medicare Advantage患者5.1次(P < 0.001)。
- 达到KOOS-JR最小临床重要差异的比例:商业保险74.8%,Medicare Advantage 75.6%,Medicare 72.7%(P = 0.35)。
局限性
- 需进一步研究评估非手术治疗模式的成本效益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: While insurance claims database studies have reported on costs before total knee arthroplasty (TKA), the cost-efficacy of nonoperative treatment remains unclear in patients who eventually undergo TKA. Furthermore, we hypothesized that patients undergoing primary TKA would have lower costs in the year following surgery than if patients continued nonoperative treatment. The purpose of this study was to determine the costs of various nonoperative treatment modalities in the year before and following primary TKA. METHODS: We reviewed a consecutive series of 13,117 patients undergoing primary TKA from 2020 to 2022 at a single institution with claims data from Medicare and a single commercial payer. We recorded all office visits, intra-articular injections, bracing, physical therapy, and imaging in the 12 months before and immediately following the patient's primary TKA, analyzing costs by the payer. Patient-reported outcome scores, readmissions, and reoperations were also noted, and costs were included in the 12-month postoperative analysis. RESULTS: There were 5,516 (42.1%) patients who were insured by Medicare, 5,044 (38.5%) commercially insured and 2,557 (19.4%) insured by Medicare Advantage The mean total cost in the year before and after TKA declined from $760 to $598 (commercial), $583 to $351 (Medicare Advantage), and $580 to $370 (Medicare). Medicare patients had the greatest number of nonoperative treatments (6.5 versus 5.3 versus 5.1, P < 0.001) in the year before TKA. Patients in all three groups achieved the minimum clinically important difference for the Knee Injury and Osteoarthritis Outcome Score for Joint Replacement at similar rates (74.8 versus 75.6 versus 72.7%, P = 0.35). CONCLUSIONS: Patients undergoing primary TKA had lower costs in the year following surgery than they did with trial nonoperative treatment in the year prior. Further studies are needed to evaluate the cost-efficacy of nonoperative treatment modalities.
引用
- Abe EA, Tarabichi S, Lizcano JD, et al. An Analysis of Costs in the Year Before and After Total Knee Arthroplasty. J Arthroplasty. 2025. PMID: 40049561. doi:10.1016/j.arth.2025.02.071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。